Moody's Ratings (Moody's) upgraded Wolverine World Wide, Inc.'s (Wolverine) ratings, including the corporate family rating (CFR) to B2 from B3, probability of default rating (PDR) to B2-PD from B3-PD, and senior unsecured global notes rating to B3 from Caa2. The speculative grade liquidity rating (S...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
A director at Medtronic Plc sold 8,605 shares at 91.580USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Crocs, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 27 August 2025 in which we reassessed the appropriateness of the ratings in the context of the ...
A director at Wolverine World Wide Inc sold after exercising options/sold 38,676 shares at 28.410USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's di...
A director at Nike Inc gave away/sold 97,373 shares at 0.000USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Two Directors at Penumbra Inc sold 14,000 shares at between 250.000USD and 250.648USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
Moody's Ratings (Moody's) affirmed the ratings of Edwards Lifesciences Corporation (Edwards) including the Baa2 senior unsecured notes and Baa2 senior unsecured bank credit facilities. At the same time, we revised the outlook to positive from stable. The rating affirmation reflects our view that E...
A director at Crocs Inc bought 3,261 shares at 76.690USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Weyco Reports Second Quarter Sales and Earnings MILWAUKEE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Weyco Group, Inc. (NASDAQ: WEYS) (“we,” “our,” “us” and the “Company”) today announced financial results for the quarter ended June 30, 2025. Second Quarter 2025 Overview Net sales: $58.2 million (down 9% from $63.9 million in Q2 2024)Gross earnings: 43.3% of net sales (compared to 43.9% of net sales in Q2 2024)Earnings from operations: $3.9 million (down 42% compared to $6.7 million in Q2 2024)Provision for income taxes: $2.4 million (includes a $1.1 million adjustment)Net earnings: $2.3 mi...
A director at Edwards Lifesciences Corp sold 4,114 shares at 79.461USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
WEYCO Group, Inc. Second Quarter 2025 Earnings Conference Call MILWAUKEE, WI, July 09, 2025 (GLOBE NEWSWIRE) -- WEYCO Group, Inc. (NASDAQ: WEYS), a global marketer of footwear, plans to announce second quarter 2025 financial results after the close on Tuesday, August 5, 2025. Additionally, Thomas W. Florsheim, Jr., Chairman and CEO, will host a conference call on Wednesday, August 6, 2025, at 11:00 a.m. Eastern Time to discuss the financial results in more detail. To participate in the call, you will first need to pre-register online. Pre-registration takes only a few minutes, and you m...
Two Directors at Deckers Outdoor Corp bought/sold after exercising options 2,125 shares at between 109.076USD and 109.764USD. The significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...
We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...
Weyco Reports First Quarter Sales and Earnings MILWAUKEE, May 06, 2025 (GLOBE NEWSWIRE) -- Weyco Group, Inc. (NASDAQ: WEYS) (“we,” “our,” “us” and the “Company”) today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Overview Net sales: $68.0 million (down 5% compared to $71.6 million in Q1 2024)Gross earnings: 44.6% of net sales (compared to 44.7% of net sales in Q1 2024)Earnings from operations: $7.0 million (down 15% compared to $8.3 million in Q1 2024)Net earnings: $5.5 million (down 17% compared to $6.7 million in Q1 2024)Diluted earnings...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.